A rare neurological disease is Sage’s last, best hope after failures in depression

Max Gelman

Senior Editor

Ryan Cross

Senior Science Correspondent

In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery, built …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A rare neurological disease is Sage’s last, best hope after failures in depression

Max Gelman

Senior Editor

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Novartis strikes radiopharma deal with Ratio worth up to $745M

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Senior Editor

Senior Science Correspondent

Sign up to read this article for free.

A rare neurological disease is Sage’s last, best hope after failures in depression